ESMO 2022: First triplet study in kidney cancer shows promising results
Sep . 21 . 2022
Research
By D’Ann George, PhD, Medical Writer https://www.youtube.com/watch?v=dUJDnoEfb0A Dr. Toni Choueiri discusses the COSMIC-313 trial. At the recent European Society of Medical Oncology congress in Paris, oncologists eagerly awaited results from the ground-breaking phase III COSMIC-313 trial for two reasons: it tested the effectiveness of a three-drug combination - cabozantinib (Cabometyx) plus nivolumab (Opdivo) and ipilimumab (Yervoy) - for the first…
Read More